How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?  Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD,

Slides:



Advertisements
Similar presentations
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Advertisements

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Pulmonary Ground-Glass Opacity (GGO) Lesions–Large Size and a History of Lung Cancer are Risk Factors for Growth  Miyako Hiramatsu, MD, Takuya Inagaki,
Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD 
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201  Hisao Asamura, MD, Tomoyuki.
Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.
Difficulties in Diagnosis and Management of Ectopic Cushing Syndrome
Electronic Updates for JTO Readers
Ground glass opacity of the lung: The veil that needs lifting
The Moth-Eaten Lung Journal of Thoracic Oncology
An Unusual Presentation of Malignant Pleural Mesothelioma
Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease  Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer  Aritoshi Hattori, MD, Takeshi Matsunaga, MD, Kazuya.
Oncological Characteristics of Radiological Invasive Adenocarcinoma with Additional Ground-Glass Nodules on Initial Thin-Section Computed Tomography:
Intraoperative Computed Tomography Navigation During Thoracoscopic Segmentectomy for Small-sized Lung Tumors  Sung Soo Chang, MD, Taku Okamoto, MD, Yoshimasa.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer  Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.
Multiple Pulmonary Chondroid Hamartoma
Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non–Small Cell Lung Cancer  Aritoshi Hattori, MD,
Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis  Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD 
Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with.
Subcategorization of Lung Cancer Based on Tumor Size and Degree of Visceral Pleural Invasion⁎  Noriaki Sakakura, MD, Shoichi Mori, MD, Katsuhiro Okuda,
Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller  Yangki Seok,
Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates.
Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response 
Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS 
Identification of a subcentimeter pulmonary adenocarcinoma using intraoperative near- infrared imaging during video-assisted thoracoscopic surgery  Jane.
Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L
Mirror Mirror on the Wall, Who Is the Fairest of Them All
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy  Yelena.
Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer  Hong Kwan Kim, MD, Yong Soo Choi,
Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD 
Matthew Reichert, MD, Eric S. Bensadoun, MD 
CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma  Mizue Hasegawa, MD, PhD,
Multiple Primary Cancers or Multiple Metastases, That Is the Question
PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD,
Multiple Pulmonary Nodules in an Elderly Woman
T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)
M. Kusumoto  Journal of Thoracic Oncology 
Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib  Nathan A. Pennell, MD, PhD, Lihong.
Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures  Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro,
Antiangiogenesis Induced Tumor Cavitation in Lung Cancer
Ethnic Differences in the Management of Lung Cancer in New Zealand
European Lung Cancer Conference (ELCC) 2016 Organisation
Andreas Rimner, MD, Kenneth E. Rosenzweig, MD 
Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD 
Nonintubated thoracoscopic surgery for pulmonary lesions in both lungs
Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD 
Journal of Thoracic Oncology
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer 
Long-Term Follow-Up of Ground-Glass Nodules After 5 Years of Stability
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib  Tatsuya.
Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy  Matthew S. Block, MD, PhD, Robert Vassallo,
A Review of First-Line Treatment for Small-cell Lung Cancer
Robert Comis, MD, The Passing of a “Lung Man”
Presentation transcript:

How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?  Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD, Shunzo Hatooka, MD, Yasushi Yatabe, MD, Tetsuya Mitsudomi  Journal of Thoracic Oncology  Volume 8, Issue 3, Pages 309-314 (March 2013) DOI: 10.1097/JTO.0b013e31827e2435 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Computed tomography images of two representative pulmonary nodules with GGO. A, A part solid (1%–25 %) GGO lesion became larger and increased the solid component (26%–50 %) after 3.3 years. B, However, a pure GGO lesion had persisted without changing in size for 6.3 years. GCO, ground-glass opacity. Journal of Thoracic Oncology 2013 8, 309-314DOI: (10.1097/JTO.0b013e31827e2435) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 The changes in size of the 108 evaluated lesions, (A) from the time of the first presentation to the last computed tomography examination. B, Some of the 69 lesions that were 1 cm or less in size became larger, (C), some of the 82 pure GGO lesions also grew in size during the observation period. GCO, ground-glass opacity. Journal of Thoracic Oncology 2013 8, 309-314DOI: (10.1097/JTO.0b013e31827e2435) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 The changes in size of all 29 lesions that grew. The changes in size between CT examinations were measured to analyze each lesion's tendency to grow. The first changes in size are shown with highly colored lines and subsequent changes are shown with light-colored lines. All 29 lesions began to grow within the first 3 years of observation. CT, computed tomography. Journal of Thoracic Oncology 2013 8, 309-314DOI: (10.1097/JTO.0b013e31827e2435) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions